Skip to main content

Table 1 Clinicopathologic factors of breast cancer patients in disease-free and progressed statuses.

From: Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression

Factors

Disease-free (n = 84)

Progresseda (n = 21)

P

n

%

n

%

Tissue visfatin

< 0.001

 ≤ 50%

51

60.7

4

19.0

 

 > 50%

33

39.3

17

81.0

 

Stage

< 0.001

 I, II

73

86.9

10

47.6

 

 III, IV

11

13.1

11

52.4

 

Grade

0.669

 1, 2

60

71.4

14

66.7

 

 3

24

28.6

7

33.3

 

Age (years)

0.002

 < 50 

51

60.7

5

23.8

 

 ≥ 50

33

39.3

16

76.2

 

BMI (kg/m2)

0.195

 < 24

53

63.1

10

47.6

 

 ≥ 24

31

36.9

11

52.4

 

Tumor size (cm)

0.007

 < 2

44

52.4

4

19.0

 

 ≥ 2

40

47.6

17

81.0

 

LN metastasis

< 0.001

 Negative

59

70.2

6

28.6

 

 Positive

25

29.8

15

71.4

 

ER

0.051

 Positive

59

70.2

10

47.6

 

 Negative

25

29.8

11

52.4

 

PR

0.139

 Positive

51

60.7

9

42.9

 

 Negative

33

39.3

12

57.1

 

HER2 status

0.417

 Positive

32

38.1

6

28.6

 

 Negative

52

61.9

15

71.4

 

Triple negative

0.031

 No

70

83.3

13

61.9

 

 Yes

14

16.7

8

38.1

 

RT

0.487

 Yes

51

60.7

11

52.4

 

 No

33

39.3

10

47.6

 

CT

0.557

 Yes

66

78.6

18

85.7

 

 No

18

21.4

3

14.3

 

HT

< 0.001

 Yes

60

71.4

6

28.6

 

 No

24

28.6

15

71.4

 
  1. BMI body mass index, LN lymph node, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, RT radiotherapy, CT chemotherapy, HT hormone therapy
  2. aProgressed patients including patients with breast cancer recurrence or patients expired during 5-year follow-up